Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer

Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer

Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active. Treatment with MMC is usually reserved for second- or third-line treatment. We have given MMC as second- or third-line treatment to 59 patients. Fifty-six patients were...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer & clinical oncology 1987-09, Vol.23 (9), p.1343-1347
Hauptverfasser: Dees, Ad, Verweij, Jaap, van Putten, Wim L.J., Stoter, Gerrit
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Chemotherapy
Female
Humans
Medical sciences
Middle Aged
Mitomycin
Mitomycins - therapeutic use
Neoplasm Metastasis
Pharmacology. Drug treatments
Retrospective Studies
Time Factors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active. Treatment with MMC is usually reserved for second- or third-line treatment. We have given MMC as second- or third-line treatment to 59 patients. Fifty-six patients were evaluable for response. No complete and only 3 partial responses were observed for an overall response rate of 5%. The median time to progression was 2 months and median survival time was 6 months. In this retrospective study MMC is demonstrated to be inactive in third-line chemotherapy.
ISSN:0277-5379
DOI:10.1016/0277-5379(87)90118-0